FRI0112 Persistence on tumour necrosis factor inhibitor (TNFI) monotherapy after achieving remission or low disease activity (LDA) on combination therapy among patients with rheumatoid arthritis (RA)

Abstract

BackgroundCombination therapy with TNFis and conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) is standard for moderate to severe RA.ObjectivesTo estimate persistence with etanercept (ETN) or other TNFi monotherapy among RA patients...